Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.6M
Filings
36
Firms Hired
3
Active Period
2006–2014
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Food and Drug Administration Reform Act of 2012
2012 · fourth_quarter · Firm: PODESTA GROUP, INC.
H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. FDA regulation of antibiotics, plasma derivatives, and rare diseases. Coverage of rare disease therapies.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5651
Food and Drug Administration Reform Act of 2012
2012 · third_quarter · Firm: PODESTA GROUP, INC.
H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. FDA regulation of antibiotics, plasma derivatives, and rare diseases.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5651
Patients' Access to Treatments Act of 2012
2012 · third_quarter · Firm: VIROPHARMA INCORPORATED
340B Drug Pricing Program; Accelerated approval; Antibiotic incentives; Bioequivalence of locally acting drugs; Drug safety/supply chain integrity; Drug shortages; Essential health benefits; Medicaid coverage; Medicare coverage and reimbursement; Orphan Drug Act; Federal grants for drug development; and H.R. 4209, Patients Access to Treatments Act of 2012 (entire bill).
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 4209
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: PODESTA GROUP, INC.
H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. FDA regulation of antibiotics, plasma derivatives, and rare diseases.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5651
Generic Drug and Biosimilar User Fee Act of 2012
2012 · second_quarter · Firm: AVENUE SOLUTIONS
S. 3187, Food and Drug Administration Safety and Innovation Act -issues related to bioequivalence for locally-acting drugs; H.R. 5651, Food and Drug Administration Reform Act of 2012 - issues related to bioequivalence for locally-acting drugs; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 - issues related to bioequivalence for locally-acting drugs; Senate working drafts of PDUFA (Prescription Drug User Fee Act) Reauthorization - issues related to bioequivalence for locally-acting drugs
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3988
Food and Drug Administration Reform Act of 2012
2012 · second_quarter · Firm: AVENUE SOLUTIONS
S. 3187, Food and Drug Administration Safety and Innovation Act -issues related to bioequivalence for locally-acting drugs; H.R. 5651, Food and Drug Administration Reform Act of 2012 - issues related to bioequivalence for locally-acting drugs; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 - issues related to bioequivalence for locally-acting drugs; Senate working drafts of PDUFA (Prescription Drug User Fee Act) Reauthorization - issues related to bioequivalence for locally-acting drugs
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5651
Generic Drug and Biosimilar User Fee Act of 2012
2012 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to bioequivalence for locally-acting drugs; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; Senate working drafts of PDUFA (Prescription Drug User Fee Act) Reauthorization
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3988
Generic Drug and Biosimilar User Fee Act of 2012
2012 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to bioequivalence for locally-acting drugs; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; Senate working drafts of PDUFA (Prescription Drug User Fee Act) Reauthorization
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3988
Source: Senate LDA